Shareholder Updates - Starpharma

Shareholder Update October 2020

Oct 20th, 2020

In this issue:

>> Starpharma is expediting the development of the SPL7013 COVID‑19 nasal spray

>> Rapid progress in the DEP^® irinotecan phase 2 & preparations underway for clinical combinations

>> DEP^® irinotecan in combination with immuno-oncology showed superior performance in colon cancer models

>> VivaGel^® BV launched in Central & Eastern Europe and Nordic region

>> Fleurstat BVgel gains expanded TGA approval to include prevention of recurrent Bacterial Vaginosis (BV) indication

>> VivaGel^® BV has now been approved in 40 countries with further submissions underway

>> Starpharma awarded $1 million MRFF funding for COVID-19 nasal spray

>> DEP^® docetaxel update & patient case study

>> DEP^® cabazitaxel update & patient case study

>> Multiple DEP^® products showcased at AACR 2020 Annual Meeting

>> New DEP^® partnership signed with Chase Sun for anti-infective program

>> AstraZeneca’s AZD0466 trial opens at MD Anderson Cancer Center

>> Starpharma creates slow release soluble DEP^® remdesivir

>> DEP^® partnering, including Antibody Drug Conjugates

>> DEP^® lutetium; impressive efficacy in human prostate cancer model

>> Outlook, Annual Report & ESG Report & recent news

Shareholder Update May 2020

May 14th, 2020

In this issue:

>> VivaGel^® BV launched in Asia

>> Fleurstat BVgel launched in NZ

>> DEP^® irinotecan phase 2 commences after positive phase 1 results

>> SPL7013 against SARS-COV-2 (coronavirus)

>> Fleurstat BVgel ranks as #1 topical BV treatment

>> Okamoto adds 11 more Asian countries to licence

>> US regulatory update

>> COVID-19: Starpharma’s operations continue with minimal disruption

>> DEP^® docetaxel, DEP^® cabazitaxel and DEP^® irinotecan

>> DEP^® patient case studies

>> AstraZeneca’s DEP^® trial ongoing in the US & US$3 million milestone payment received

>> New DEP^® ADC programs

>> DEP^® pipeline targets multiple high-value areas

>> Other DEP^® programs

>> Outlook, recent news & events

Shareholder Update January 2020

Jan 30th, 2020

In this issue:

>> VivaGel^® BV launched in the UK

>> AstraZeneca first DEP^® product enters the clinic; triggers US$3M milestone

>> DEP^® cabazitaxel trial moves into phase 2 on positive results

>> Fleurstat BVgel marketing campaign; New Zealand launch planned

>> Dual strategy to achieve approval of the NDA in the US

>> Okamoto joins forces with Japanese government for STI prevention campaign

>> VivaGel^® condom receives regulatory approval in Europe

>> DEP^® docetaxel & DEP^® cabazitaxel clinical trial case studies

>> DEP^® irinotecan phase 1/2 trial

>> New candidate - DEP^®gemcitabine

>> GMP DEP^® facility licence

>> DEP^®combinations add further value

>> Outlook, recent news & events

Shareholder Update July 2019

Jul 1st, 2019

In this issue:

>> VivaGel^® BV launched in Europe & Australia; US regulatory progress

>> VivaGel condom launched in Japan by Okamoto

>> DEP^® docetaxel & DEP^® cabazitaxel clinical trial update; DEP^® irinotecan trial start & new data

>> Starpharma signs second commercial oncology agreement with AstraZeneca

>> AstraZeneca highlights AZD0466 at 2019 ASCO meeting & upcoming US FDA IND

>> Patent published for AstraZeneca Bcl2/xL DEP conjugates

>> DEP^® radiotherapeutics

>> Outlook, recent news & events

Shareholder Update March 2019

Mar 18th, 2019

In this issue:

>> Fleurstat BVgel - Australian launch

>> Mundipharma's European launch of VivaGel^® BV

>> Mundipharma's international roll-out of VivaGel^® BV

>> FDA meeting to discuss VivaGel^® BV approval in the US

Download: Shareholder Update March 2019 (pdf file, 453kb)

Shareholder Update January 2019

Jan 17th, 2019

In this issue:

>> FDA requests further data for VivaGel^® BV approval in the US

>> Launch of VivaGel^® BV in multiple territories

>> VivaGel^® BV licensed to ITF Pharma in the US

>> VivaGel^® condom approved in Japan

>> Clinical trials for internal DEP^® products progressing well

>> Patent published for AstraZeneca-DEP^® drugs: DEP^® Bcl2/xL inhibitors show compelling efficacy & synergy in combination

>> DEP^® docetaxel & DEP^® cabazitaxel outperformed both gemcitabine & Abraxane^®

>> SPL7013 eye drops for viral conjunctivitis

>> Partnering activities

>> Macquarie initiates coverage of Starpharma

>> Outlook

Download: Shareholder Update January 2019 (pdf file, 557kb)

Shareholder Update February 2018

Feb 19th, 2018

In this issue:

>> New sites open for the DEP^® docetaxel phase 2 trial

>> DEP^® cabazitaxel phase 1 / 2 trial commences

>> VivaGel^® BV NDA submission lodged under Fast Track program

>> VivaGel^® BV approved by TGA

>> DEP^® irinotecan progressing towards the clinic

>> AstraZeneca-Starpharma collaboration

>> Extensive global licensing negotiations for VivaGel^® BV

>> Positive market research findings for VivaGel^® BV

>> Q2 Cashflow Report at 31 December 2017

>> OTCQX market recognition

>> Starpharma News & Events

>> Outlook

Download: Shareholder Update February 2018 (pdf file, 1.5mb)

Shareholder Update October 2017

Oct 18th, 2017

In this issue:

>> DEP^® docetaxel achieves positive phase 1 results and commences phase 2

>> AZ presents first DEP^® candidate AZD0466 – a Bcl2/xL inhibitor

>> Successful VivaGel^® BV phase 3 results

>> Update on other internal DEP^® candidates

>> Grant awarded to Starpharma-Monash

>> Starpharma and Peter Mac Cancer Centre awarded grant

>> FY17 Financial results; >$60M cash at 30 June

>> Annual Report and Annual General Meeting

>> Starpharma News & Events

Download: Shareholder Update October 2017 (pdf file, 1.3mb)

Shareholder Update July 2017

Jul 4th, 2017

In this issue:

>> Starpharma sells Agrochemicals business to Agrium for $35M cash

>> DEP^® irinotecan outperforms irinotecan in multiple cancer models

>> DEP^® docetaxel, DEP^® cabazitaxel and scale-up facilities

>> AstraZeneca pays US$2M DEP^® milestone to Starpharma

>> VivaGel^® BV phase 3 results timing and commercialisation

>> VivaGel^® condom launched in Canada

>> Sale of Ansell's Sexual Wellness division

>> Starpharma News & Events

Download: Shareholder Update July 2017 (pdf file, 710kb)

Shareholder Update January 2017

Jan 19th, 2017

In this issue:

›› Enrolment completed for phase 3 program: VivaGel^® BV for prevention of recurrence

›› VivaGel^® BV granted QIDP and Fast Track designation by US FDA

›› Favourable revision to FDA guidance for BV Treatment

›› VivaGel^® condom approved in Canada; licensed in China and Iran

›› New DEP^® partnered programs with AstraZeneca and world leading antibody-drug conjugate companies

›› DEP^® docetaxel phase 1 program in final expansion phase; preparations underway for phase 2

›› DEP^® cabazitaxel shows no neutropenia

›› DEP^® irinotecan internal program shows superior performance

Download: Shareholder January 2017 (pdf file, 751kb)

Shareholder Update April 2016

Apr 13th, 2016

In this issue:

> Message from the CEO

> Adama licenses Priostar^®for 2,4-D

> DEP^TMcabazitaxel shows superior performance

> Starpharma's Targeted DEP^TMconjugates - compelling results in an area of high interest

> AstraZeneca selects second DEP^TM candidate

> Starpharma long standing collaborator ranked 4th in the world

> Starpharma signs licence with Aspen for commercialisation of VivaGel^® BV in Australia and New Zealand

> MOU for VivaGel^® condom in China

> Half-year financial results

> Bio-Europe^® conference

Download: Shareholder Update April 2016 (pdf file, 1MB)

Shareholder Update October 2015

Oct 29th, 2015

In this Issue:

› EU marketing approval granted for VivaGel^® BV
› Multi-product DEP^® license with AstraZeneca
› VivaGel^® BV: Symptomatic Relief and Treatment of BV/Prevention of recurrence
› VivaGel^® condom
› Phase 1 DEP® docetaxel trial update

› Agrochemicals
› Starpharma in the News
› Starpharma full year financial results

› Presentations and conferences

Download: Shareholder Update October 2015 (pdf file, 994kb)

Shareholder Update March 2015

Mar 23rd, 2015

In this Issue:

› Phase 1 DEP™ docetaxel clinical trial update
› DEP™ docetaxel in the news
› Partner news
› Starpharma targeting key growth areas in Oncology
› Bacterial vaginosis: Prevention of recurrence/Symptomatic relief
› VivaGel® condom
› Corporate news
› Starpharma half yearly financial results

Download: Shareholder Update March 2015 (pdf file, 1MB)